S2. Rituximab for ANCA-associated vasculitis: the UK experience
- PMID: 23490639
- DOI: 10.1016/j.lpm.2013.01.049
S2. Rituximab for ANCA-associated vasculitis: the UK experience
Similar articles
-
S3. Rituximab for ANCA-associated vasculitides: the French experience.Presse Med. 2013 Apr;42(4 Pt 2):534-6. doi: 10.1016/j.lpm.2013.01.050. Epub 2013 Feb 26. Presse Med. 2013. PMID: 23453207 Review. No abstract available.
-
L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?Presse Med. 2013 Apr;42(4 Pt 2):643-50. doi: 10.1016/j.lpm.2013.01.047. Epub 2013 Mar 6. Presse Med. 2013. PMID: 23474045 Review. No abstract available.
-
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.N Engl J Med. 2014 Nov 6;371(19):1771-80. doi: 10.1056/NEJMoa1404231. N Engl J Med. 2014. PMID: 25372085 Clinical Trial.
-
L44. Management of relapses in vasculitis.Presse Med. 2013 Apr;42(4 Pt 2):619-22. doi: 10.1016/j.lpm.2013.02.307. Epub 2013 Mar 7. Presse Med. 2013. PMID: 23477710 Review. No abstract available.
-
Efficacy of remission-induction regimens for ANCA-associated vasculitis.N Engl J Med. 2013 Aug 1;369(5):417-27. doi: 10.1056/NEJMoa1213277. N Engl J Med. 2013. PMID: 23902481 Free PMC article. Clinical Trial.
Cited by
-
Systemic vasculitis and headache.Curr Opin Neurol. 2023 Dec 1;36(6):631-646. doi: 10.1097/WCO.0000000000001223. Epub 2023 Oct 12. Curr Opin Neurol. 2023. PMID: 37865837 Free PMC article. Review.
-
Treatment of primary systemic necrotizing vasculitides: the role of biotherapies.Clin Exp Nephrol. 2013 Oct;17(5):622-627. doi: 10.1007/s10157-013-0860-2. Epub 2013 Sep 10. Clin Exp Nephrol. 2013. PMID: 24018402 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources